Ore Pharmaceutical Holdings Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ore Pharmaceutical Holdings Inc.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Urotronic set to complete a $20m series C, bringing its total funding to $61m for the development of drug-eluting balloon-based urology products.
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
- Other Names / Subsidiaries
- Gene Logic Inc.
- Ore Holdings Inc.
- Ore Pharmaceuticals, Inc.